Adaptive Biotechnologies Corp (ADPT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Shareholders held by Adaptive Biotechnologies Corporation on June 5, 2026. The report details the voting results for three proposals submitted to security holders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report regarding shareholder voting and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document reports the successful ratification of the Board of Directors, executive compensation, and the independent auditor.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of voting results. The filing confirms that a quorum was present and that all three proposals were approved by the shareholders. No specific risks, contingencies, or unusual items are disclosed in this text.
Key Facts for Investors
- Director Election: Robert Hershberg, PhD, MD, was elected with 71.81% of votes submitted, while Katey Owen, PhD, was elected with 97.72% of votes submitted.
- Executive Compensation: The advisory vote on 2025 named executive officer compensation passed with 96.55% support.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 99.50% support.
- Broker Non-Votes: There were 13,570,859 broker non-votes recorded for the director elections and the executive compensation vote, but zero for the auditor ratification.